Lv1
20 积分 2024-04-30 加入
Effects of orelabrutinib, a BTK inhibitor, on antibody-mediated platelet destruction in primary immune thrombocytopenia
4个月前
已完结
Real-World Outcomes with Orelabrutinib in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: A Retrospective Study
4个月前
已完结
Review Crit Rev Oncol Hematol . 2025 Sep 1:215:104917. doi: 10.1016/j.critrevonc.2025.104917. Online ahead of print. From R-CHOP to revolution: How CAR T-Cells, ADCs, and bispecific antibodies are transforming DLBCL treatment
6个月前
已完结
DLBclass: a probabilistic molecular classifier to guide clinical investigation and practice in diffuse large B-cell lymphoma
6个月前
已完结
皖公网安备34019202002308
